Cellectar BioSciences Inc. has entered into a multi-year strategic supply agreement with Ionetix Corporation to secure clinical and commercial-scale supplies of two key alpha-emitting radioisotopes, Actinium-225 (Ac-225) and Astatine-211 (At-211). This collaboration will support Cellectar's development of targeted alpha therapies (TATs) for cancer treatment, ensuring a reliable source of high-quality isotopes for its drug development programs, including future clinical trials and potential commercial launches. The agreement leverages Ionetix's cyclotron technology and production capabilities to meet the growing demand for these critical isotopes as Cellectar advances its radiotherapeutic pipeline.